What is the interaction between valproic acid (VPA) and phenytoin?

Interaction Between VPA and Phenytoin

Valproic acid (VPA) significantly interacts with phenytoin through two distinct mechanisms: it displaces phenytoin from plasma protein binding sites (increasing free phenytoin by 40-90%) and inhibits phenytoin metabolism, resulting in elevated free phenytoin levels that can cause toxicity even when total phenytoin levels appear therapeutic. 1, 2

Mechanism of Interaction

The VPA-phenytoin interaction operates through a dual mechanism that creates a complex clinical picture:

Protein Binding Displacement

• VPA displaces phenytoin from albumin binding sites, increasing the free (unbound) fraction by 60-90% 1, 3
• This displacement causes total phenytoin levels to decrease or remain unchanged while free phenytoin levels increase significantly 4, 3
• The free fraction of phenytoin increases from baseline ~10% to 15-19% with VPA co-administration 3

Metabolic Inhibition

• VPA inhibits hepatic metabolism of phenytoin, further increasing free drug concentrations 5, 6
• This metabolic inhibition compounds the effect of protein displacement 4, 3
• The combination results in 18-25% increase in unbound phenytoin AUC despite stable or decreased total levels 4

Critical Clinical Implications

The most dangerous aspect of this interaction is that patients can develop phenytoin toxicity with total phenytoin levels in the "therapeutic range" (10-20 μg/mL). 7, 3 This occurs because:

• Standard therapeutic drug monitoring measures total phenytoin concentration
• The therapeutic effect and toxicity correlate with free (unbound) phenytoin concentration
• When VPA is added, the relationship between total phenytoin and clinical effect becomes unreliable 5

Signs of Phenytoin Toxicity

Monitor for: ataxia, nystagmus, tremor, somnolence, and altered consciousness 2, 7

Management Recommendations

When Adding VPA to Phenytoin Therapy

1. Reduce phenytoin dose by approximately 25-30% when initiating VPA 1
2. Monitor free (unbound) phenytoin levels rather than total levels if available 3, 8
3. If only total phenytoin monitoring available, expect therapeutic effects at lower total concentrations than usual (potentially 8-12 μg/mL rather than 10-20 μg/mL) 5
4. Closely monitor for clinical signs of toxicity regardless of total phenytoin levels 7

When Adding Phenytoin to VPA Therapy

1. Start with standard phenytoin loading dose but anticipate need for lower maintenance doses 1
2. Obtain baseline and follow-up drug levels within 24-48 hours 7
3. Adjust based on clinical response and free phenytoin levels when possible 3

Monitoring Strategy

• Check phenytoin levels within 24-48 hours after adding or adjusting either drug 7
• Request free phenytoin levels in patients with hypoalbuminemia or when total levels seem discordant with clinical picture 8
• In critically ill patients with hypoalbuminemia, free phenytoin monitoring is essential as protein binding is further reduced 8

Bidirectional Effects on VPA

Phenytoin also affects VPA levels through enzyme induction:

• Phenytoin induces VPA metabolism, potentially requiring doubled VPA doses to maintain therapeutic levels, particularly in children 5
• This effect is more pronounced with chronic co-administration 5

Alternative Considerations

For status epilepticus or acute seizures, consider levetiracetam as an alternative to avoid this interaction entirely 9, 10. Levetiracetam has comparable efficacy to both phenytoin and VPA without significant drug interactions 9, 11.

Key Pitfall to Avoid

Never assume phenytoin toxicity is absent based solely on total phenytoin levels being in the "therapeutic range" when VPA is co-administered. Clinical assessment and free phenytoin levels (when available) are essential for safe management 7, 5, 3.